1 – 2 of 2
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
(
- Contribution to journal › Article
- 2015
-
Mark
A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma.
(
- Contribution to journal › Article